BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it has successfully ...

Company’s ultra-sensitive biomarker technology supports latest scientific evidence from study published in Science that Epstein-Barr virus (EBV) increases susceptibility toward multiple sclerosis (MS) ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today unveiled ...

Accelerator Lab Revenue -- $8.3 million, comprised of $5.3 million Simoa and $3 million Spatial, with Q4 performance exceeding expectations, especially in consumables and lab services. Academic ...

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that the HD-X Simoa Immunoassay ...

Powering Precision Health 2022 Alzheimer’s podcast announced in recognition of Biomarker Factory launch “Researchers are exploring the utility of ultrasensitive plasma biomarkers for drug trial ...

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the inclusion of a new dried blood ...

Ultra-sensitive Simoa® HD-X technology powers new findings that detect rapid reduction of plasma P-tau217 from donanemab, Lilly’s investigational antibody therapy for Alzheimer's disease at 12 weeks ...

Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its Simoa ® technology has powered important advances in ongoing clinical ...